<DOC>
	<DOC>NCT01473797</DOC>
	<brief_summary>ECLA is a phase II, multicenter study testing sub cutaneous cladribine 0.1mg/kg/j during 5 days, administrated every month for 4 courses, in symptomatic adult patients with pulmonary Langerhans cell histiocytosis and impairment of lung function patients.</brief_summary>
	<brief_title>Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis</brief_title>
	<detailed_description>ECLA is a phase II, multicenter study testing sub cutaneous cladribine 0.1mg/kg/j during 5 days, administrated every month for 4 courses, in symptomatic adult patients with pulmonary Langerhans cell histiocytosis and impairment of lung function patients.</detailed_description>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>Age 18 to 55 yr Histologically proven pulmonary Langerhans cell histiocytosis ( patients with presumptive diagnosis whose lung function precludes lung biopsy may be included after revision of their medical record at the national reference center for Langerhans cell histiocytosis) Symptomatic pulmonary Langerhans cell histiocytosis (NYHA dyspnea class ≥2) with: irreversible airflow obstruction (FEV1/FVC&lt;70%) with postbronchodilator FEV1 comprised between 30 and 70% of predicted and/or decrease ≥15% in FEV1, FVC or DLCO as compared to baselines values in the year preceding the inclusion Signed written informed consent Women at childbearing age without adequate contraception or wishing breastfeeding Male without adequate contraception during the study Dyspnea due to severe pulmonary arterial hypertension (PAP≥35mmHg) confirmed by cardiac right catheterism Previous malignancy Current infectious disease Renal failure Liver failure Severe alteration of lung Hematologic disease unrelated to Langerhans cell histiocytosis Epilepsy Hepatic, spleen or hematology involvement by Langerhans cell histiocytosis Pneumothorax within a month previously to inclusion Previous treatment with cladribine Contra indication to the use of cladribine Previous myelosuppressive treatment Simultaneous participation to another interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>